Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | CASP7 | P55210 | 2/20 | 0.47 |
| ▸ | CASP6 | P55212 | 2/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.47 |
| ▸ | CASP9 | P55211 | 1/20 | 0.47 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19678 | 0.69 | — | — | |
| SCHEMBL1451688 | 0.67 | MAOA (0.46) | CA12CA9PARP1CASP3CASP7 | |
| SCHEMBL4818277 | 0.67 | CA12 (1.00) | CA12CA9PARP1CASP3CASP7 | |
| SCHEMBL14896 | 0.67 | CA12 (1.00) | CA12CA9PARP1CASP3CASP7 | |
| SCHEMBL29355184 | 0.67 | CA12 (1.00) | CA12CA9PARP1CASP3CASP7 | |
| SCHEMBL7454690 | 0.67 | MAOA (0.52) | CA12CA9PARP1CASP3CASP7 | |
| SCHEMBL209077 | 0.67 | MAOA (0.38) | TSHRMAOAMAOBCES1ALDH1A1 | |
| SCHEMBL30212315 | 0.65 | TDP2 (0.66) | CA12CA9PARP1CASP3CASP7 | |
| SCHEMBL23070369 | 0.65 | CA12 (0.54) | CA12CA9PARP1CASP3CASP7 | |
| Water SCHEMBL19462706 | 0.65 | CA12 (0.95) | CA12CA9PARP1CASP3CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1548 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515947-B | SHP2 inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| WO-2023064195-A1 | CGRP ANTAGONISTS FOR TREATING TRIGEMINAL NEURALGIA | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-04-20 | — | — | WO | claimed |
| WO-2023034467-A2 | CGRP ANTAGONISTS FOR TREATING SKIN CONDITIONS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | claimed |
| WO-2023034466-A1 | CGRP ANTAGONISTS FOR TREATING PSORIASIS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | claimed |
| US-RE49361-E1 | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-01-10 | — | — | US | claimed |
| CN-115515947-A | SHP2 inhibitor and composition and application thereof | 贝达药业股份有限公司 | 2022-12-23 | — | — | CN | claimed |
| US-20210363175-A1 | 9(11)-UNSATURATED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2021-11-25 | — | — | US | claimed |
| CN-113227114-A | 9(11) -unsaturated neuroactive steroids and methods of use thereof | 萨奇治疗股份有限公司 | 2021-08-06 | — | — | CN | claimed |
| WO-2020163236-A1 | TREATING LONG QT SYNDROME | THE GENERAL HOSPITAL CORPORATION (US) | 2020-08-13 | — | — | WO | claimed |
| WO-2020082065-A1 | 9(11)-UNSATURATED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | claimed |
| EP-1299352-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-04-09 | — | — | EP | claimed |
| WO-2003002122-A1 | BETA-HYDROXYAMINE DERIVATIVES USEFUL IN TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-09 | — | — | WO | claimed |
| WO-2002094768-A2 | AZA HYDROXYLATED ETHYL AMINE COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2002-11-28 | — | — | WO | claimed |
| US-20020143177-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-10-03 | — | — | US | claimed |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2002002506-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| EP-0406119-B1 | New peptide derivatives, process of their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1994-01-19 | — | — | EP | claimed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | claimed |
| US-5098888-A | Cholinergic agents and antispasmodic agents | ADIR ET COMPAGNIE (FR) | 1992-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143177-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, CHAT | CA12 890/4885CA9 1842/4885PARP1 2619/4885 |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | CA12 1161/4885CA9 2277/4885PARP1 2861/4885 |
| US-20210363175-A1 | 9(11)-UNSATURATED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, GRIN2B, HTR1B | CA12 2411/4885CA9 1778/4885PARP1 4586/4885 |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, CHAT | CA12 1075/4885CA9 1930/4885PARP1 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.